Mario Sznol

Mario Sznol has been a pioneer in combination checkpoint immunotherapy for advanced and metastatic melanoma, contributing to early development and clinical investigation of nivolumab and ipilimumab combinations. His research on CheckMate clinical trials helped establish ipilimumab plus nivolumab as a highly active combination regimen for advanced melanoma with durable long-term benefit. He has extensively investigated immune-related adverse events from combination checkpoint blockade, developing management strategies that allow effective treatment while mitigating serious toxicity. His contributions span from early phase I trials of anti-PD-1 therapy through contemporary management of refractory metastatic melanoma.